Kodiak Sciences (NASDAQ:KOD) and Genocea Biosciences (NASDAQ:GNCA) Head to Head Comparison
Genocea Biosciences (NASDAQ:GNCA – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...
Le Lézard2d
Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas' High-Density Microarray Patch (HD-MAP) Delivery Technology
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of data supporting the effective use of its high-density microarray patch ...
Business Wire3d
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...
StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)
StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology ...
University of Geneva4d
Vaccine immunology
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site ...
Targeted Oncology6d
FDA Grants RMAT Designation to Nogapendekin Alfa in Pancreatic Cancer
The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...
Pulmonology Advisor6d
Cardiac Sarcoidosis Detected in 10% of Pulmonary Sarcoidosis Cases
Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...